Cellular Therapy Manuals

The sections below provide instructions for completing the Cellular Therapy Essential Data Pre-Infusion Form (F4000), Cellular Therapy Product Form (F4003), Cellular Therapy Infusion Form (F4006), and Cellular Therapy Essential Data Follow-Up Form (F4100).

Below are scenarios describing when autologous cellular therapy data can be collected in the context of patient consent for research:

⭐ Reporting of cellular therapy infusions to CIBMTR remains voluntary. Reporting of commercially available cellular therapy product infusions (i.e. Kymriah®, Yescarta™, Tecartus™, Breyanzi™, Abecma®, Carvykti™) is strongly encouraged.

Cell therapy follow up schedule
As part of the Summer 2022 release, a reporting track will now be set for all cell therapy CRIDs reported to the CIBMTR. The track will be set by the center reporting preference and infusion type. There are five cellular therapy reporting tracks:

- Standard
- 15 year
- 100 day only
- No follow up
- CTRM

See the Data Management Guide for a full description of each track.

Cell therapy reporting preferences:
As part of the Summer 2022 release, every center will have a reporting preference. The options are:

- Do Not Perform
- Perform Do Not Report
- Research Level
- Regulatory Level

Please see the Data Management Guide for a full description of the different levels, including which forms will come due.

Follow up tracks as set by reporting preference
As part of the Summer 2022 release, the center reporting preference is now used in determining the cell therapy reporting track, and subsequently which forms are required.
When to report cellular therapy infusions to the CIBMTR

Please see the Data Management Guide for a full description the guidance when determining whether to report a cellular therapy to the CIBMTR.

**Donor cellular infusion (DCI)**

Donor cellular infusions (DCIs) are a subtype of cellular therapy.

An infusion can be classified as a “DCI” when:

- The intent is something other than to restore hematopoiesis
- The infusion must be post-HCT, often by the same donor as the HCT
- Indication is suboptimal donor chimerism, immune reconstitution, GVHD treatment, prevent or treat disease relapse (as reported on F4000)
- Composition of cells include mesenchymal cells, peripheral blood mononuclear cells, NK cells, etc.

Donor Lymphocyte Infusions (DLIs) are a subset of DCIs. DLIs meet the same criteria above but are infusions of just a lymphocyte product. DLIs are reported on the Donor Lymphocyte Infusion (2199) form.

<table>
<thead>
<tr>
<th>Infusion type</th>
<th>Genetically modified</th>
<th>Product type</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>yes</td>
<td>commercially available product</td>
<td>Kymriah, Yescarta, etc.</td>
</tr>
<tr>
<td>Stand alone cell therapy</td>
<td>non-commercial</td>
<td>clinical trial products</td>
<td>15yr No follow up</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n/a</td>
<td>Standard No follow up</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VSTs</td>
<td>Standard No follow up</td>
</tr>
<tr>
<td></td>
<td>no</td>
<td>commercially available product</td>
<td>15yr No follow up</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n/a</td>
<td>Standard No follow up</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VSTs</td>
<td>Standard No follow up</td>
</tr>
<tr>
<td></td>
<td>no</td>
<td>commercially available product</td>
<td>n/a 100 day only</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n/a</td>
<td>100 day only</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DCI (excludes DLI)</td>
<td>100 day only</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Research level</th>
<th>Regulatory level</th>
</tr>
</thead>
<tbody>
<tr>
<td>consent</td>
<td>consent</td>
</tr>
<tr>
<td>no consent</td>
<td>no consent</td>
</tr>
</tbody>
</table>

**Date** | **Manual Section** | **Add/Remove** | **Description** | **Reasoning** (If)

---

3500: Subsequent Neoplasms
4000: Cellular Therapy Essential Data Pre-Infusion
4003: Cellular Therapy Product
4006: Cellular Therapy Infusion
4100: Cellular Therapy Essential Data Follow-Up
<table>
<thead>
<tr>
<th>Date</th>
<th>Version</th>
<th>Modify</th>
<th>Update Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/8/23</td>
<td>4000: Cellular Therapy Essential Data Pre-Infusion</td>
<td>Modify</td>
<td>Updated the text in the blue box below question 121: Serologic tests should be completed during the pre-HCT work-up phase, or approximately one month prior to the start of the preparative regimen. If a recipient tests positive for Hepatitis B core antibody (Anti HBc), Hepatitis B surface antigen (HBsAg), Hepatitis B NAAT, Hepatitis C antibody (Anti HCV), and/or Hepatitis C NAAT serologic tests, also complete the HEP Form (Form 2047). If a recipient tests positive for HIV antibody or HIV NAT serologic tests, also complete the HIV Form (Form 2048).</td>
</tr>
</tbody>
</table>
**4000: Cellular Therapy Essential Data Pre-Infusion**

This form must be completed for all recipients of cellular therapy (non-HCT) with or without a prior HCT. CAR T cells, tumor-infiltrating lymphocytes, and cytotoxic T cells are common cellular therapies that should be reported using this form. Regenerative medicine indications can be reported using this form with the exception of genetic modified hematopoietic stem cells to treat malignant hematologic or other non-malignant indications. These infusions are considered transplants and should be reported using the Pre-Transplant Essential Data (Pre-TED) Form 2400.

For recipients of hematopoietic cellular transplants (HCT), complete the Pre-TED (2400) and Disease Classification (2402) forms.

Donor Lymphocyte Infusions (DLI) are no longer captured on the Pre-CTED (4000) form. An infusion can be classified as a DLI when:

- It's an infusion of a lymphocyte-only product
- The infusion must be post-Allogeneic HCT and will most likely be from the same HCT donor
- The product cannot be genetically modified

Donor Lymphocyte Infusion (2199) form should be completed.

This form reflects baseline recipient data and indication for a course of cellular therapy. All cellular therapies (non-HCT) are collected on this form, including indications that reflect donor cellular infusions (DCI) done post-transplant, now referred to as “post-HCT cellular therapy”. A course of cellular therapy includes all infusions given per protocol, or when multiple infusions are given for the same indication using the same product/donor (e.g., post-HCT cellular therapy (DCI)).

Multiple infusions of commercially available products require a separate Pre-Cellular Therapy Essential Data (4000) forms for each infusion.

The use of cellular therapy is expanding. Treatment strategies include isolation and transfer of specific stem cell populations, administration of effector cells (e.g. cytotoxic T-cells), induction of mature cells to become pluripotent cells, and reprogramming of mature cells (e.g., CAR T-cells).

---

**Consent Status and Baseline Forms**

There has been a change to the functionality of submitting the Pre-Transplant Essential Data (2400), Pre-Transplant Essential Data Disease Classification (2402), and Pre-Cellular Therapy Essential Data (4000) forms. If a consent status has not yet been reported for a recipient, the edit form icon will appear disabled (see Figure 1 below). When the user hovers over the icon, it will display that consent has not yet been reported for that recipient (see Figure 2 below). The user should go to the Consent Tool (see Navigation to the Consent Tool) and document the recipient’s consent status in order to enable the edit icon.
and allow for completion of the form.

**Figure 1.** Disabled Edit Form Icon

![Disabled Edit Form Icon](image1)

**Figure 2.** Hovered Text, Consent Not Yet Reported

![Hovered Text](image2)

**Links to sections of form:**
- Q1-17: Recipient Data
- Q18-32: Cellular Therapy and HCT History
- Q33-57: Product Identification
- Q58-77: Indication for Cellular Therapy
- Q78-84: Lymphodepleting Therapy Prior to Cellular Therapy
- Q85-88: Toxicity Prophylaxis
- Q89-99: Hematologic Findings Prior to Lymphodepleting Therapy
- Q100-102: Functional Status
- Q103-113: Comorbid Conditions

**Manual Updates:**
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, please click here or reference the retired manual section on the [Retired Forms Manuals](#) webpage.

<table>
<thead>
<tr>
<th>Date</th>
<th>Manual Section</th>
<th>Add/ Remove</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>Section</td>
<td>Action</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------</td>
<td>--------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>10/17/2022</td>
<td>Q113-127: Comorbid Conditions</td>
<td>Modify</td>
<td>Removed the following text: Indicate whether the total serum ferritin result was Known or Unknown prior to the start of lymphodepleting therapy. If Known, report the result and the unit of measure in question 102, and report the date (MM-DD-YYYY) of the test in question 103.</td>
</tr>
<tr>
<td>9/29/2022</td>
<td>Q113-127: Comorbid Conditions</td>
<td>Add</td>
<td>Added blue note box above question 122: Prior to answering Were there any co-existing diseases or organ impairment present according to the HCT comorbidity index (HCT-CI) question, review the list of co-existing disease(s) and/or organ impairments listed below.</td>
</tr>
<tr>
<td>9/29/2022</td>
<td>Q113-127: Comorbid Conditions</td>
<td>Modify</td>
<td>Updated text in red: Current Diagnosis at the Time of Pre- Infusion Evaluation</td>
</tr>
<tr>
<td>9/29/2022</td>
<td>Q113-127: Comorbid Conditions</td>
<td>Modify</td>
<td>Moved ‘Rheumatologic’ and ‘Prior malignancy, requiring treatment’ to the Documented medical history list. Added ‘heart value disease’ under Current Diagnosis at the Time of Pre-Infusion Evaluation</td>
</tr>
<tr>
<td>9/29/2022</td>
<td>Q113-127: Comorbid Conditions</td>
<td>Modify</td>
<td>Removed text from the blue note box: Hepatic and Renal Comorbidities Report all comorbidities including those that are considered complications of the primary disease for infusion. See examples below.</td>
</tr>
</tbody>
</table>

_Last modified: Oct 17, 2022_
Q1-17: Recipient Data

Question 1: Ethnicity

The recipient’s ethnicity is automatically populated based on the value reported in the CRID assignment tool in FormsNet3. Verify the recipient’s ethnicity is correct. If an error is noted, correct the error in the CRID assignment tool and verify the recipient’s ethnicity has been updated on the Pre-Cellular Therapy Essential Data (4000) form.

Question 2: Race: (check all that apply)

The recipient’s race is automatically populated based on the value reported in the CRID assignment tool in FormsNet3. Verify the recipient’s race is correct. If an error is noted, correct the error in the CRID assignment tool and verify the recipient’s race has been updated on the Pre-Cellular Therapy Essential Data (4000) form.

Question 3: Country of primary residence

Select the recipient’s country of residence. If the recipient’s country of primary residence is Brazil, continue with question 4. If the recipient’s country of primary residence is Canada, continue with question 5. If the recipient’s country of primary residence is the United States, continue with question 6.

Question 4: State of residence of recipient (for residents of Brazil)

If Brazil was selected as the recipient’s primary country of residence, enter the recipient’s state of permanent residence at the time of infusion.

Question 5: Province or territory of residence of recipient (for residents of Canada)

If Canada was selected as the recipient’s primary country of residence, enter the recipient’s providence or territory of permanent residence at the time of infusion.

Question 6: State of residence of recipient (for residence of USA)

If the United States was selected as the recipient’s primary country of residence, enter the recipient’s state of permanent residence at the time of infusion.

Question 7: Zip or postal code for place of recipient’s residence (USA and Canada recipients only)

Enter the five-digit ZIP code in which the recipient resides. Only five digits are required, the last four digits are optional; however, if the ZIP+4 (nine digit) code is available, please report it in this field. The zip or postal code is required for USA residents. The postal code is optional for Canadian residents. The question can be answered or left blank without error for Canadian residents.
Question 8: Was this infusion received within the context of a clinical trial?

Products that are commercially available are no longer under a clinical trial. However, if a commercial product is being used within the context of a clinical trial for a new indication or the product is “out of specification”, report the clinical trial in this question.

For the infusion being reported on this form, indicate if the recipient is a registered participant with BMT-CTN, RCI-BMT, USIDNET, COG, a Corporate / Industry trial, EudraCT, UMIN, an investigator-initiated trial and/or another clinical trial sponsor, regardless if that sponsor uses CIBMTR forms to capture outcomes data. If “yes,” continue with question 9 to report the sponsor. If “no,” continue with question 16. If the infusion is enrolled in multiple studies, even if from the same sponsor, report each study separately.

- **BMT-CTN**: Blood and Marrow Transplant Clinical Trials Network
- **RCI-BMT**: Resource for Clinical Investigation in Blood and Marrow Transplant
- **USIDNET**: United States Immunodeficiency Network
- **COG**: Children’s Oncology Group
- **Corporate / Industry**
- **ANZCTR**: Australian New Zealand Clinical Trials Registry
- **EudraCT**: European Clinical Trials Database
- **UMIN**: University Hospital Medical Information Network Center
- **Investigator initiated**

**Questions 9 – 15 Reporting Participation in More Than One Study**

FormsNet³SM application: Complete questions 9 – 15 for each study the recipient is participating in by adding an additional instance in the FormsNet³SM application.

Paper form submission: Copy questions 9 – 15 and complete for each study the recipient is participating in.

**Question 9 – 15: Study sponsor:**

Select the study sponsor of the clinical trial. Click on the link above for more information about each organization.

If the study sponsor is reported as **BMT-CTN, RCI-BMT, USIDNET, COG, or Investigator initiated**, specify the ClinicalTrials.gov identification number in question 15. The letters “NCT” do not need to be included in the field. Investigator initiated trials include those that are initiated and managed by a non-pharmaceutical / company investigator (e.g., individual physicians or cooperative groups) and center specific trials or multi-center trials.

If the recipient is participating in a corporate or industry sponsored trial, indicate the study sponsor as **Corporate / Industry**, specify the name of the Corporate or Industry sponsor in question 10 and report the clinicaltrials.gov ID number in question 15. Corporate / Industry examples include, but are not limited to,
Atara Biotherapeutics, Bellicum Pharmaceuticals, BlueBird Bio, Celgene, Daiichi Sankyo, Iovance Biotherapeutics, Janssen Pharmaceuticals, Juno Therapeutics, Kite Pharma, Mesoblast, Miltenyi Biotec and Novartis. Corporate / Industry name will be reported on the Cellular Therapy Product (4003) form.

Products that are commercially available are no longer under a clinical trial. However, if a commercial product is being used within the context of a clinical trial for a new indication or the product is “out of specification”, report the clinical trial in this question.

If the recipient is participating in an Australian New Zealand Clinical Trials Registry trial, indicate the sponsor as ANZCTR and specify the ACTRN number in question 11 (not the recipient ID). The ANZCTR, established in 2005, is an online public registry of clinical trials. The ANZCTR accepts both interventional and observational studies for registration from all countries and from the full spectrum of therapeutic areas including trials of pharmaceuticals, surgical procedures, preventive measures, lifestyle, devices, treatment and rehabilitation strategies and complementary therapies. The ACTRN number is alpha-numeric, starting with "ACTRN".

If the recipient is participating in a European Medicines Agency clinical trial, indicate the study sponsor as EudraCT 9 and specify the study identification number in question 12 (not the recipient ID). The European Union Drug Regulating Authorities Clinical Trials is the European Clinical Trials Database of all clinical trials of investigational medicinal products with at least one site in the European Union commencing May 1, 2004, or later. The EudraCT number has the format YYYY-NNNNNN-CC, where YYYY is the year in which the number is issued, NNNNNN is a six-digit sequential number, and CC is a check digit.

If the recipient is participating in a study with UMIN, indicate the study sponsor as UMIN and specify the alpha-numeric study identification number in question 13 (not the recipient ID). UMIN was established in 1989 as a cooperative organization national medical school in Japan, sponsored by the Ministry of Education, Culture, Science, Sports and Technology (MEXT), Japan.

If the recipient is participating in a clinical trial and the study sponsor is not listed, select Other, specify the sponsor’s name in question 14, and report the ClinicalTrials.gov identification number in question 15.

ClinicalTrials.gov Identification Number
All clinical trials are required to be registered on the clinicaltrials.gov website and will have an associated identification number. Report the number in question 15, do not include the letters “NCT” that precede the digits.

Question 16-17: Was this infusion received outside the context of a clinical trial?

This question is not applicable if the infusion is received within the context of a clinical trial.

Indicate Yes if the recipient is receiving cellular therapy outside of the context of a clinical trial and in one of the following settings:
• **Institutional guidelines/standard of treatment:** Internal protocols at the center.

*Select Institutional guidelines/standard of treatment if the product is commercially available (Kymriah®, Yescarta®, Tecartus™, Breyanzi™, Abecma®, Carvykti™)*

• **Hospital exemption:** Applicable when giving cell therapy product without a clinical trial, the hospital that produces the cells must be the hospital that gives the cells.

• **Compassionate use:** No protocol is available or approved by institution, the physician asks for a one-time use.

If the recipient is not receiving the cellular therapy outside the context of a clinical trial, select No and continue with question 18.

**Section Updates:**

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
</tr>
</tbody>
</table>

*Last modified: Sep 23, 2022*
**Q18-32: Cellular Therapy and HCT History**

**Question 18: Is this the first time the recipient is being treated using a cellular therapy (non-HCT)?**

This is defined as the first application of a cellular therapy the recipient ever receives, not the first application the recipient receives at your facility. The intent is to capture the full picture of the recipient’s treatment history.

If this is the first application of a cellular therapy the recipient has ever received or it is not known if this is the first cellular therapy, select Yes or Unknown, respectively and continue with question 27. If this is not the first time the recipient has received a cellular therapy, select No and continue with question 19.

**Question 19: Were all prior cellular therapies (non-HCT) reported to the CIBMTR?**

This should include any / all infusions not performed at your center. If the recipient had a prior infusion, the past infusion dates can be found in the Recipient Information Grid in FormsNet3SM. Contact CIBMTR Center Support if there are questions.

If all prior cellular therapies were reported to the CIBMTR or it is not known if all cellular therapies were reported to the CIBMTR, select Yes or Unknown, respectively and continue to question 27. If all cellular therapies were not reported to the CIBMTR, report No and continue with question 20.

**Question 20: Specify the number of prior cellular therapies:**

Enter the number of prior cellular therapies for the recipient. A “cellular therapy event” is defined as the infusion or administration of a cellular therapy product for treatment of a specific indication(s). Each infusion or administration of a cellular product should be counted separately. Include all infusions the recipient received, even if they were not performed at your center. The intent is to capture the full picture of the recipient’s treatment history. It is not expected to complete forms for prior unreported infusions.

**Questions 21 – 26 Reporting Prior Cellular Therapies**

- **FormsNet3SM application:** Complete questions 21-26 to report all prior cellular therapies that have not yet been reported to the CIBMTR by adding an additional instance in the FormsNet3SM application.
- **Paper form submission:** Copy questions 21-26 and complete for each prior cellular therapy that has not yet been reported to the CIBMTR.

**Question 21: Date of the prior cellular therapy:**

Report the date (YYYY-MM-DD) of the prior cellular therapy for the reported instance. If the exact date is unknown and must be estimated, check the “date estimated” box.

For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.
Question 22: Was the cellular therapy performed at a different institution?

Indicate Yes or No if the prior cellular therapy reported in this instance was performed at another institution. If Yes, report the name and address of the institution in question 23.

**Question 23: Specify the institution that performed the prior cellular therapy:**

Report the name, city, state, and country of the institution where the recipient’s prior cellular therapy being reported in this instance was performed. These data are used to identify and link the recipient’s existence in the database and, if necessary, obtain data from the other institution where the previous treatment was administered.

**Question 24 – 25: Specify the primary indication for the prior cellular therapy:**

Select the indication for the prior cellular therapy reported in this instance. Any indication that is followed by “(post-HCT)” or “(with HCT)” requires a prior HCT also be reported to CIBMTR.

If the indication for the prior cellular therapy is not listed, select Other indication and specify the indication in question 25. If the indication for the prior cellular therapy is not documented, select Unknown.

**Question 26: What was the cell source for the prior cellular therapy? (check all that apply)**

Indicate the cell source(s) for the prior cellular therapy reported in this instance. If the product is “off the shelf” or a “third party donor” product obtained from pharmaceutical companies or other corporate entities, the donor type should still be identified.

An Autologous product has cells collected from the recipient for his / her own use.

An unrelated donor (Allogeneic, unrelated) is a donor who shares no known ancestry with the recipient. Include adoptive parents / children or stepparents / children.

A related donor (Allogeneic, related or syngeneic) is a blood-related relative. This includes monozygotic (identical twins), non-monozygotic (dizygotic, fraternal, non-identical) twins, siblings, parents, aunts, uncles, children, cousins, half-siblings, etc.

**Questions 27 – 32 HCT History**

When both HCT and CT forms are submitted at the same time, duplicate questions will exist between the F2400 and F4000. To reduce the reporting burden, duplicated questions, including HCT history, on the Cell Therapy forms are disabled.

**Question 27: Has the recipient ever had a prior HCT?**

Include all HCTs in the recipient’s history, even if the transplants were not performed at your center. The intent is to capture the full picture of the recipient’s treatment history.
If the recipient has had a prior HCT, select **Yes**. If the recipient has not had a prior HCT, select **No** or **Unknown**, respectively and continue with question 33.

**Question 28: Were all prior HCTs reported to the CIBMTR?**

This should include any / all infusions not performed at your center. If the recipient had a prior infusion, the past infusion dates can be found in the Recipient Information Grid in FormsNet3SM. Contact CIBMTR Center Support if there are questions.

If all prior HCTs were reported to the CIBMTR or it is not known if all HCTs were reported to the CIBMTR, select **Yes** or **Unknown**, respectively and continue with question 33. If all HCTs were not reported to the CIBMTR, select **No**.

**Question 29: Date of the prior HCT:**

Report the date (YYYY-MM-DD) of the prior HCT reported in this instance.

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.

**Questions 30 – 31: Was the HCT performed at a different institution?**

Indicate **Yes** or **No** if the prior HCT reported in this instance was performed at another institution. If **Yes**, report the name, city, state, and country of the institution where the recipient’s prior HCT reported in this instance was performed in question 31. These data are used to identify and link the recipient’s existence in the database and, if necessary, obtain data from the previous transplant center.

If the prior HCT was not performed at a different institution, select **No** and continue with question 32.

**Question 32: Specify the HSC source(s) for the prior HCT: (check all that apply)**

Indicate the applicable cell source(s) for the prior HCT being reported in this instance.

An **Autologous product** has cells collected from the recipient for his/her own use.

An **unrelated donor (Allogeneic, unrelated)** is a donor who shares no known ancestry with the recipient. Include adoptive parents / children or stepparents / children.

A **related donor (Allogeneic, related)** is a blood-related relative. This includes monozygotic (identical twins), non-monozygotic (dizygotic, fraternal, non-identical) twins, siblings, parents, aunts, uncles, children, cousins, half-siblings, etc.

**Section Updates:**

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
</table>
Q33-56: Product Identification

Question 33: Are any of the products associated with this course of cell therapy genetically modified?

Genetically modified products include any product that was manipulated to alter its gene expression through the insertion of different genes or editing of genes. An example of a genetically modified product is the manipulation of T-lymphocytes to express Chimeric Antigen Receptors (CAR T-cells) directed towards specific tumor targets (antigens). If more than one product is infused, indicate if any of the products are genetically modified. This question is used to determine the follow up schedule of the cellular therapy.

Questions 34-52 Reporting Donor Information

FormsNet3SM application: Complete questions 34-52 to report all donors, per protocol, by adding an additional instance in the FormsNet3SM application.

Paper form submission: Copy questions 34-52 and complete for all donors, per protocol.

Question 34: Specify donor:

Indicate the donor type for this product. If the product is “off the shelf” or a “third party” donor product obtained from pharmaceutical companies or other corporate entities, donor type should still be identified.

An **Autologous** product has cells collected from the recipient for his / her own use.

A **related donor** (Allogeneic, related) is a blood-related relative. This includes syngeneic, monozygotic (identical) twins, non-monozygotic (dizygotic, fraternal, non-identical) twins, siblings, parents, aunts, uncles, children, cousins, half-siblings, etc. Do not include adoptive parents/children or stepparents/children.

An **unrelated donor** (Allogeneic, unrelated) is a donor who shares no known ancestry with the recipient. Include adoptive parents/children or stepparents/children.

Question 35: Did NMDP/Be the Match facilitate the procurement, collection, or transportation of the product?

Indicate whether NMDP / Be the Match facilitated the procurement, collection, or transportation of the product. This information is included on the product label, the paperwork accompanying the product, and within the NMDP search / product documentation.

Question 36: Was the product a cord blood unit?

Indicate Yes if the product was a cord blood unit or was derived from a cord blood unit.

- If the product was an *autologous* cord blood unit, report the non-NMDP CBU ID in question 42.
- If the product was a *related* cord blood unit, report the non-NMDP CBU ID in question 42.
- If the product was an *NMDP unrelated* cord blood unit, report the NMDP CBU ID in question 40.
- If the product was a *non-NMDP unrelated* cord blood unit, report the non-NMDP CBU ID in question
42.

Indicate No if the product was not a cord blood unit.

- If the autologous product was not a CBU, continue with question 50.
- If the product was related and not a CBU, specify the related donor type in question 37 then continue with question 45 to report donor date of birth.
- If the unrelated donor was NMDP and not a CBU, report the GRID in question 42.
- If the unrelated donor was non-NMDP and not a CBU, report the non-NMDP unrelated donor ID in question 40.

**Question 37: Specify the related donor type (allogenic, related only)**

Indicate the relationship and match between the recipient and the related donor reported in this instance.

**Syngeneic:**

*Includes:* Monozygotic (identical) twins. Occurs when a single egg is fertilized to form one zygote, which then divides into two separate embryos.

*Does not include:* Other types of twins or HLA-identical siblings (see below).

**HLA-identical sibling:**

*Includes:* Non-monozygotic (dizygotic, fraternal, non-identical) twins. Occurs when two eggs are fertilized by two different sperm cells at the same time. This category also includes siblings who aren’t twins but have identical HLA types. The patient and donor will be allele-level matched at HLA-A, B, C, and DRB-1.

*Does not include:* Half-siblings should be reported as “HLA matched other relative”, if their HLA typing is a match, or “mismatched relative” if it does not match.

**HLA-matched other relative:**

*Includes:* All blood relatives, other than siblings, who are HLA matched (e.g., parents, aunts, uncles, children, cousins, half-siblings). The patient and donor will be allele-level matched at HLA-A, B, C, and DRB-1.

*Does not include:* Adoptive parents/children or stepparents/children who are HLA matched.

**HLA-mismatched relative:**

*Includes:* Siblings who are not HLA-identical and all other blood relatives who have at least one HLA mismatch (mismatch can be at the antigen or allele level) (e.g., parents, aunts, uncles, children, cousins, half-siblings). The patient and donor will be allele-level mismatched at one or more loci (HLA-A, B, C, or DRB-1).

*Does not include:* Adoptive parents/children or stepparents/children.

**Question 38: Was this donor used for any prior cellular therapies or HCT? (for this recipient)**

Indicate if the allogeneic unrelated or related donor reported in this instance was used for prior cellular therapies or HCT for this recipient. If this is the recipient's first infusion, select No.
**Question 39: Global Registration Identifier for Donors (GRID):**

The Global Registration Identifier for Donors (GRID) was developed by the WMDA to ensure secure, reliable and unambiguous assignment of unrelated donors. The GRID standard is a 19-character donor identifier composed of three elements: Issuing Organization Number (ION), Registration Donor Identifier, and Checksum (shown below). This standard will ensure each donor ID is globally unique and will reduce the risk of misidentification of donors or their donations.

[Image of GRID standard]


**Question 40: NMDP Cord Blood Unit:**

Report the NMDP unrelated cord blood unit ID. This information is included on the product label, the paperwork accompanying the product, and within the NMDP search/product documentation. The ID is always numeric and begins with “9” (e.g., 9000-0000-0). If the product ID does not begin with a “9,” the product may not be an NMDP cord blood unit and the source of the product should be double-checked. Enter the NMDP unrelated cord blood unit ID.

**Question 41: Registry ID: (not applicable for related donors)**

Report the non-NMDP unrelated donor ID. Examples of non-NMDP donor registries include, but are not limited to: Anthony Nolan, Australia Bone Marrow Donor Registry, and REDOME. This ID is often located on the product label, the paperwork accompanying the product, and registry-specific search/product documentation. Enter the non-NMDP unrelated donor ID.

**Question 42: Non-NMDP cord blood unit ID: (include related and autologous CBUs)**

Report the non-NMDP cord blood unit ID. Examples of non-NMDP donor registries include but are not limited to: St. Louis Cord Blood Bank and StemCyte International Cord Blood Center. This ID is often located on the product label, the paperwork accompanying the product, and registry-specific search/product documentation. Enter the non-NMDP cord blood ID.

Note that some cord blood banks can ship their units either through the NMDP or directly to the transplant center. Carefully review the accompanying documentation to determine which is appropriate for your unit. You may wish to consult with your center’s Transplant Coordinator, as he or she will have insight as to how the product was acquired.
**Question 43-44: Registry or UCB Bank ID:**

Report the registry or UCB Bank ID used to obtain the adult donor or umbilical cord blood unit.

The Bone Marrow Donors Worldwide (BMDW) codes have been adopted to avoid submitting the entire name and address of the donor registry. Some common banks that do not list with BMDW have been added to the FormsNet3 list, including St Louis Cord Blood Bank (SLCBB) and Viacord (VIAC).

The registry code for NMDP donors is USA1 and for NMDP cord units is U1CB.

If the donor was found through DKMS, report the registry that facilitated the HCT. Some registries may be listed more than once with BMDW (one way for marrow/PBSC products and differently for cord blood products). Ensure that the appropriate code for the product was selected because distribution of data depends on the code.

If the BMDW website does not list a match code for the adult donor registry or cord blood bank, provide the registry’s official name in question 44. Ensure the entered registry in question 44 is not already listed in the pull-down list for question 43. For example, NMDP adult donors, NMDP cords, and New York Cord Bank each have their own entries above in the registry or UCB Bank ID drop down menu.

**Question 45-46: Donor date of birth:**

Report if the donor’s date of birth is Known or Unknown. If the donor’s date of birth is known, report the date of birth (YYYY-MM-DD) in question 46 and continue with question 49.

**Question 47-48: Donor age:**

If the donor’s DOB is unknown, report if the donor’s age is Known or Unknown. If the donor’s age is known, report the donor’s age at the time of product collection in question 48. Report the age in months if the recipient is less than 1 year old, otherwise report the age in years.

**Question 49: Donor sex:**

Indicate the donor’s biological sex as Male or Female. For cord blood units, report the infant donor’s sex.

**Question 50: Specify the total number of products: (per protocol, as part of this course of cellular therapy)**

For infusions of Breyanzi™ (both commercially available and non-conforming products),
Report the total number of products infused per protocol. This question is used to make the correct number of Cellular Therapy Product Forms (Form 4003) come due. Each product must be part of the protocol and will be given regardless of disease response.

**Example 1.** A series of collections from the same donor that uses the same collection method even if the collections are performed on different days, should be considered a single cellular therapy product if only one set of manufacturing steps are applied to the collected material.

**Example 2.** Products from the same donor but obtained using different manufacturing steps are considered different products and require multiple product forms.

**Example 3.** If the cells were manipulated or modified by different methods and at the end of the manufacturing process are combined for a single infusion or administration, it will be considered a single product and it will require a single Cellular Therapy Product Forms (Form 4003).

Donor lymphocyte infusions (DLIs) should be reported on the Donor Lymphocyte Infusion (2199) form.

**Question 51-52: Name of product:**

This question is limited to commercially available or pre-commercial products and is used for study enrollment and validation. If the name of the product is not an option, select Other product and specify the name in question 52. If the product has no name, such as clinical trial or study product select No product name from the list.

The product name selected here will be auto populated onto subsequent forms and used to disable questions where the information is not made available to sites (i.e., manufacturing or cell dose).

**Question 53: In what setting is this cell therapy product infusion being planned?**

Indicate if this cell therapy product infusion will be administered as an Inpatient or Outpatient procedure.

**Question 54: Is a subsequent HCT part of the overall treatment protocol?**

This question intends to capture instances where the cellular therapy is administered in association with an HCT, either planned or dependent upon the response to the cellular therapy. It is not intended to capture an HCT given prior to this cellular therapy infusion. If, at the time of the current infusion, a subsequent HCT is planned according to the protocol, check Yes even if the recipient does not receive the planned subsequent HCT. The word “planned” should not be interpreted as: if the recipient relapses, then the “plan” is to perform
a subsequent HCT. If a subsequent HCT is not planned as part of the overall treatment protocol, select No and continue with question 57.

**Question 55: Specify the HCT type:**

Specify the type of the subsequent HCT that is planned as part of the overall treatment protocol.

- **Autologous product** has cells collected from the recipient for his / her own use.
- **Allogeneic product** is from a donor who is not the recipient, either related or unrelated to the recipient.

**Question 56: Specify the circumstances which the subsequent HCT will be performed:**

Specify the reason for which the subsequent HCT will be performed as Regardless of response to cellular therapy, Only if the patient responds to cellular therapy, or Only if the patient fails to respond or has an incomplete response.

**Section Updates:**

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
</tr>
</tbody>
</table>

_Last modified: Sep 23, 2022_
Q57-76: Indication for Cellular Therapy

Question 57: What was the primary indication for performing treatment with cellular therapy?

From the list provided, select the primary indication for which the recipient is receiving the cellular therapy.

If the indication is in the list below and the cell therapy is being given with HCT or post-HCT, no additional consent is required from the patient per CIBMTR. Please confirm with your local IRB:

- GVHD prophylaxis (with HCT)
- GVHD treatment (post-HCT)
- Immune reconstitution (post-HCT)
- Infection prophylaxis
- Prevent disease relapse (post-HCT)
- Suboptimal donor chimerism (post-HCT)

The Disease Classification (2402) Form will come due if the indication is reported as Malignant hematologic disorder, Non-malignant disorder, or Solid tumor. This allows CIBMTR to capture disease specific information for cellular therapy utilizing an existing form to maintain consistency in data collection.

If the recipient is receiving post-HCT cellular therapy (e.g., DCI) for relapsed, persistent, or progressive disease, the indication should be recorded as Malignant hematologic disorders and complete a new Disease Classification (2402) form for the disease that has relapsed / persisted / progressed. This will capture / confirm the diagnosis and reporting the disease status prior to the DCI.

If the indication for cellular therapy is cardiovascular disease, musculoskeletal disorder, neurologic disease, ocular disease or pulmonary disease, follow up on the Cellular Therapy Essential Data Follow-Up (4100) form is not required.

Disease Classification Questions
The newest versions of the TED forms use the World Health Organization (WHO) disease classifications. The disease classification questions contain all of the established WHO disease types and subtypes. The “other indication” category should be used only if the recipient’s disease is not one of the listed options. For more information regarding disease classification, visit the WHO website and consult a transplant physician, as needed. If any questions remain after review with the transplant physician, visit the WHO website or contact CIBMTR Center Support if there are questions.

Malignant vs. Non-Malignant
Malignant disease involves cells dividing without control that can spread to other parts of the body through blood and lymph systems. These diseases are usually characterized by
unlimited, aggressive growth, invasion of surrounding tissues, and metastasis. Non-malignant tumors involve cell overgrowth but lack the malignant properties of cancer. Non-malignant diseases include severe aplastic anemia, disorders of the immune system, inherited disorders of metabolism, etc. The CIBMTR database disease codes are represented in parentheses after the disease subtype on the Disease Classification questions and can be helpful in mapping diagnosis [e.g., Myeloid Sarcoma (295)] and determining if the disease is malignant or non-malignant. Disease codes (10-299) indicate a malignant disease, with the exception of Paroxysmal Nocturnal Hemoglobinuria (PNH) (56). A disease code of (300) or above indicates a non-malignant disease, with the exception of disease code (900), which could indicate either a malignant or non-malignant disease.

**Question 58: Date of diagnosis:**

If the primary indication for the cellular therapy is cardiovascular disease, musculoskeletal disease, neurologic disease, ocular disease, pulmonary disease, infection treatment or other indication, report the diagnosis date of the primary indication. The diagnosis date for malignant hematologic disorder, non-malignant disorder or solid tumor will be captured on the Disease Classification (2402) form.

Report the date (YYYY-MM-DD) of the first pathological diagnosis (e.g., bone marrow or tissue biopsy) of the disease for which the patient is receiving cellular therapy. Enter the date the sample was collected for examination. If the indication is infection, report the date of diagnosis as the collection date for the first positive microbiology culture. If the diagnosis was determined at an outside center, and no documentation of a pathological or laboratory assessment is available, the dictated date of diagnosis within a physician note may be reported. Do not report the date symptoms first appeared.

If the recipient was diagnosed prenatally (in utero) or if the indication is a congenital disorder, report the date of birth as the date of diagnosis.

If the exact pathological diagnosis date is not known, use the process described in General Instructions, General Guidelines for Completing Forms.

**Question 59-61: Specify cardiovascular disease:**

If cardiovascular disease is the indication for cellular therapy, indicate the specific disease. If Other cardiovascular disease is selected, specify the other cardiovascular disease in question 60. If Other peripheral vascular disease is selected, specify the other peripheral vascular disease in question 61.

Report “induced cardiomyopathy” as Heart failure (non-ischemic etiology) (703).

**Question 62-63: Specify musculoskeletal disorder:**

If musculoskeletal disorder is the indication for cellular therapy, indicate the specific disorder. If Other musculoskeletal disorder is selected, specify the other musculoskeletal disorder in question 63.
**Question 64-65: Specify neurologic disease:**

If neurologic disease is the indication for cellular therapy, indicate the specific disease. If the specific disease is not explicitly listed, select the broad category for the primary indication for infusion.

If **Other neurologic disease** is selected, specify the other neurologic disease in question 65.

**Question 66: Specify ocular disease:**

If ocular disease is the indication for the cellular therapy, specify the ocular disease. Examples include treatment of glaucoma or photoreceptor degeneration.

**Question 67-68: Specify pulmonary disease:**

If pulmonary disease is the indication for the cellular therapy, specify the pulmonary disease. If **Other pulmonary disease** is selected, specify the other pulmonary disease in question 68.

**Question 69-75: Specify the organism for which the cellular therapy is being given to treat:**

If infection treatment is the indication for the cellular therapy, indicate the organism(s) being treated in questions 69-75.

**Organism:**

From Table 1 entitled “Codes for Commonly Reported Organisms”, select the code corresponding to the identified organism as indicated on the microbiology report, laboratory report, or other physician documentation. Report the code in the boxes provided on the form.

**Fungal infections:** Note the inclusion of Pneumocystis (formerly found under parasites). The most commonly found fungal infections are Candida (C. albicans), Aspergillus (A. fumigatus), and Fusarium sp.

**Viral infections:** Caused by exposure to a new virus or reactivation of a dormant virus already present in the body. The most common viral infections are due to HSV (Herpes Simplex Virus), and CMV (Cytomegalovirus). If the site of CMV is the lung, confirm whether the patient had interstitial pneumonitis rather than CMV pneumonia.

**Table 1: Codes for Commonly Reported Organisms**

<table>
<thead>
<tr>
<th>Code</th>
<th>Organism</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>210</td>
<td>Aspergillus, NOS</td>
<td>503 Suspected fungal infection</td>
</tr>
<tr>
<td>211</td>
<td>Aspergillus flavus</td>
<td>304 Adenovirus</td>
</tr>
<tr>
<td>212</td>
<td>Aspergillus fumigatus</td>
<td>341 BK Virus</td>
</tr>
<tr>
<td>213</td>
<td>Aspergillus niger</td>
<td>344 Coronavirus (excluding COVID-19) (SARS-CoV-2))</td>
</tr>
<tr>
<td></td>
<td></td>
<td>309 Human Immunodeficiency Virus 1 or 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>343 Human metapneumovirus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>322 Human Papillomavirus (HPV)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>349 Human T-lymphotropic Virus 1 or 2</td>
</tr>
<tr>
<td>Code</td>
<td>Organism/Pathogen</td>
<td>Code</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>215</td>
<td>Aspergillus terreus</td>
<td>350</td>
</tr>
<tr>
<td>214</td>
<td>Aspergillus ustus</td>
<td>303</td>
</tr>
<tr>
<td>270</td>
<td>Blastomyces (dermatitidis)</td>
<td>347</td>
</tr>
<tr>
<td>201</td>
<td>Candida albicans</td>
<td>346</td>
</tr>
<tr>
<td>208</td>
<td>Candida non-albicans</td>
<td>325</td>
</tr>
<tr>
<td>271</td>
<td>Coccidioides (all species)</td>
<td>327</td>
</tr>
<tr>
<td>222</td>
<td>Cryptococcus gattii</td>
<td>326</td>
</tr>
<tr>
<td>221</td>
<td>Cryptococcus neoformans</td>
<td>328</td>
</tr>
<tr>
<td>230</td>
<td>Fusarium (all species)</td>
<td>318</td>
</tr>
<tr>
<td>261</td>
<td>Histoplasma (capsulatum)</td>
<td>306</td>
</tr>
<tr>
<td>241</td>
<td>Mucorales (all species)</td>
<td>307</td>
</tr>
<tr>
<td>260</td>
<td>Pneumocystis (PCP / PJP)</td>
<td>308</td>
</tr>
<tr>
<td>242</td>
<td>Rhizopus (all species)</td>
<td>340</td>
</tr>
<tr>
<td>272</td>
<td>Scedosporium (all species)</td>
<td>301</td>
</tr>
<tr>
<td>240</td>
<td>Zygomycetes, NOS</td>
<td>317</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Question 76: Specify other indication**

If the indication for the cellular therapy does not fit into a category listed, specify the **other indication**. This option should be used sparingly. Contact CIBMTR Center Support with any questions prior to using this field.
### Section Updates:

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
</tr>
</tbody>
</table>

*Last modified: Sep 23, 2022*
Q77-83: Lymphodepleting Therapy Prior to Cellular Therapy

Question 77: Was lymphodepleting therapy given prior to the infusion? (does not include lines of therapy given for disease treatment, bridging therapy, or maintenance)

Lymphodepleting therapy is given to destroy lymphocytes (e.g., T cells). Indicate Yes or No if the lymphodepleting therapy was given prior to the infusion. Do not include therapy given to treat disease – this therapy should be reported on the disease specific form, if applicable.

Question 78: Height at start of lymphodepleting therapy:

Report the recipient’s height just prior to the start of the lymphodepleting therapy. The intent of this question is to determine the height used when calculating lymphodepleting therapy drug doses. This height is usually documented on the infusion orders or admitting orders. Report height to the nearest whole centimeter or inch (round up if 0.5 or greater).

Question 79: Weight at start of lymphodepleting therapy:

Report the recipient’s actual body weight just prior to the start of the lymphodepleting therapy. The intent of this question is to report the actual weight at the time the lymphodepleting therapy starts (which may be different than the weight used to determine lymphodepleting therapy doses). This weight is usually documented on the infusion orders or admitting orders. Report weight to the nearest tenth of a kilogram or pound. Do not report adjusted body weight, lean body weight, or ideal body weight.

Questions 80 – 81: Specify lymphodepleting drugs

The form lists each drug by the generic name.

For each lymphodepleting drug administered, check the box to indicate the drug was given as part of the lymphodepleting therapy used prior to the cellular therapy infusion.

Select Other drug and specify the drug name in question 81 only if the lymphodepleting drug is not listed as an option. If more than one “other” drug is prescribed, each “other” drug should be reported in a separate instance. List the generic name of the drug in the space provided and attach a copy of the source document using the attachment feature in FormsNet3SM.
Question 82: Total prescribed dose:

Report the *total* prescribed dose of each drug in mg/m\(^2\) as stated in the protocol. Do not report the prescribed daily dose. Report the drug doses to the nearest tenth.

Question 83: Date started:

Report the date (YYYY-MM-DD) the drug was first administered. If the exact date is unknown, review the General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.

Copy and complete questions 80-83 to report all drugs given as lymphodepleting therapy.

Section Updates:

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Last modified: Sep 23, 2022
Q84-87: Toxicity Prophylaxis

Question 84-85: Therapy given for the prevention of CRS: (prophylactic therapy)

Presently, CRS prophylaxis is not routinely performed. However, practices related to CRS are evolving rapidly and some programs have considered using drugs like tocilizumab preemptively in patients with high risk to develop serious CRS. If therapy was given for the prevention of CRS check all that apply from the list of the drugs given. If Other therapy is selected, specify the therapy in question 85.

If more than one “other” drug is prescribed, report each “other” drug in the specify field. List the generic name of the drug in the space provided and attach a copy of the source document using the attachment feature in FormsNet3SM.

Question 86-87: Therapy given for the prevention of neurotoxicity (ICANS: (prophylactic therapy))

For ICANS, anti-epileptic drugs are often prescribed to prevent seizures. The intent of this question to separate the use of these drugs from prevention to treatment of seizure, which is captured in F4100. Additionally and similar to CRS, practices are evolving rapidly, and other drugs might be used to prevent ICANS among patients with high risk for serious manifestations of this complication. If therapy was given for the prevention of neurotoxicity (ICANS), check all that apply from the list of the drugs given. If Other therapy is selected, specify the therapy in question 87.

If more than one “other” drug is prescribed, report each “other” drug in the specify field. List the generic name of the drug in the space provided and attach a copy of the source document using the attachment feature in FormsNet3SM.

Section Updates:

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Last modified: Sep 23, 2022
Q88-109: Hematologic Findings Prior to Lymphodepleting Therapy

Question 88: Date complete blood count (CBC) sample drawn:

These questions are intended to determine the clinical status of the recipient prior to the start of lymphodepleting therapy for cellular therapy. Testing may be performed multiple times within the pre-infusion work-up time period; report the most recent CBC obtained. Laboratory values obtained on the first day of the lymphodepleting therapy may be reported as long as the blood was drawn before any lymphodepleting therapy was administered.

If no lymphodepleting therapy is given, report most recent CBC result prior to the cellular infusion.

Questions 89-96: Complete blood count results available: (check all that apply)

For each cell type listed, checking the box will indicate a result is available. Provide the most recent laboratory values from the CBC on the date reported in the prior question.

WBC: The white blood cell count is a value that represents all of the white blood cells in the blood. If the count is too high or too low, the ability to fight infection may be impaired.

Neutrophils: Neutrophils are a subtype of white blood cell that fights infection. The value on the laboratory report may be a percentage or an absolute value. If an absolute value is reported, divide it by the white blood cell count for a percentage. Neutrophils are also known as polymorphonuclear leukocytes (PMNs).

Lymphocytes: Lymphocytes are another subtype of white blood cell that fights infection. The value on the laboratory report may be a percentage of an absolute value. If an absolute value is reported, divide it by the white blood cell count for a percentage.

Hemoglobin: Hemoglobin is a molecule in red blood cells that delivers oxygen to tissues throughout the body. A low hemoglobin count is considered “anemia” and blood transfusions, or growth factors may be required to increase the hemoglobin level.

Hematocrit: The hematocrit is the percentage (sometimes displayed as a proportion) of red blood cells relative to the total blood volume. A low hematocrit may require red blood cell transfusions or growth factors. Indicate if the recipient received a red blood cell transfusion within 30 days prior to obtaining the blood sample.

If a hematocrit value is reported, also indicate if the recipient received a red blood cell transfusion within 30 days prior to the date of the CBC reported in question 88.

Platelets: Platelets are formed elements within the blood that help with coagulation. A low platelet count, called thrombocytopenia, may lead to easy bleeding or bruising. Thrombocytopenia may require platelet transfusions. Indicate if the recipient received a platelet transfusion within 7 days prior to testing.
If a platelet value is reported, also indicate if the recipient received a platelet transfusion within 7 days prior to the date of the CBC reported in question 88.

**Question 98: Did the recipient receive any growth factors <7 days before the start of systemic therapy?**

Indicate if the recipient received any growth factor (e.g., GCS-F) within 7 days prior to the start of systemic therapy (i.e. lymphodepleting therapy). If no systemic therapy was given, indicate if the recipient received any growth factor (e.g., GCS-F) within 7 days prior to the infusion. In the event of a long acting growth factor (e.g., pegfilgrastim (Neulasta®), please answer this question as yes if the recipient received it within 14 days prior.

**Question 99-101: LDH**

Testing may be performed multiple times within the pre-infusion work-up time period; report the most recent LDH value obtained within 30 days of the start of lymphodepleting therapy. Laboratory values obtained on the first day of the lymphodepleting therapy may be reported as long as the blood was drawn before any lymphodepleting therapy was administered. If no lymphodepleting therapy is given, report most recent LDH result prior to the cellular infusion.

Indicate whether the LDH result was Known or Unknown prior to the start of lymphodepleting therapy. If Known, report the result, the unit of measure, and specify the upper limit of normal in question 101.

**Question 102-103: Total serum ferritin:**

Ferritin is a protein that stores, transports, and release iron. Iron is toxic to cells, so it is stored within the ferritin protein for use. Ferritin that is too low might be indicative of iron deficiency related anemia. Ferritin that is too high might be indicative of iron overload. It is tracked for some diseases, such as hemophagocytic lymphohistiocytosis (HLH).

Date Sample Collected: Testing may be performed multiple times within the pre-infusion work-up time period; report the most recent total serum ferritin value obtained within 30 days of the start of lymphodepleting therapy. Laboratory values obtained on the first day of the lymphodepleting therapy may be reported as long as the blood was drawn before any lymphodepleting therapy was administered.

**Question 104-107: C-reactive protein:**

Testing may be performed multiple times within the pre-infusion work-up time period; report the most recent C-reactive protein value obtained within 30 days of the start of lymphodepleting therapy. Laboratory values obtained on the first day of the lymphodepleting therapy may be reported as long as the blood was drawn before any lymphodepleting therapy was administered.

Indicate whether the C-reactive protein result was Known or Unknown prior to the start of lymphodepleting therapy. If Known, report the date (MM-DD-YYYY) of the test in question 105, report the result and the unit of measure in question 106, and specify the upper limit of normal in question 107.
**Question 108-109: Serum creatinine:**

Creatinine is a normal metabolic waste that is primarily filtered from the blood by the kidneys and then excreted in the urine. Since it is generally produced at a constant rate, the clearance rate and the serum level are widely used as indicators of kidney function.

Testing may be performed multiple times within the pre-infusion work-up time period; report the most recent serum creatinine value obtained. Laboratory values obtained on the first day of the lymphodepleting therapy may be reported as long as the blood was drawn before any lymphodepleting therapy was administered.

Report the result and the unit of measure in question 108 and report the date (MM-DD-YYYY) of the test in question 109.

**Section Updates:**

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>102-103</td>
<td>10/17/2022</td>
<td>Modify</td>
<td>Removed the following text: <em>Indicate whether the total serum ferritin result was Known or Unknown prior to the start of lymphodepleting therapy. If Known, report the result and the unit of measure in question 102, and report the date (MM-DD-YYYY) of the test in question 103.</em></td>
<td>This question does not have known/unknown options</td>
</tr>
</tbody>
</table>
Q110-112: Functional Status

Specify the functional status of the recipient immediately prior to the start of lymphodepleting therapy or the cellular therapy if no lymphodepleting therapy was given.

**Question 110:** What scale was used to determine the recipient’s functional status prior to the cellular therapy?

The CIBMTR uses the Karnofsky / Lansky scale to determine the functional status of the recipient immediately prior to the start of the cellular therapy. The Karnofsky Scale is designed for recipients aged 16 years and older and is not appropriate for children under the age of 16. The Lansky Scale is designed for recipients one year old to less than 16 years old. For recipients less than one year old, questions 111-112 should be left blank.

Select the appropriate performance scale, Karnofsky or Lansky, based on the recipient’s age.

**Question 111-112:** Performance score prior to the cellular therapy:

Recipient performance status is a critical data field that has been determined to be essential for all outcome-based studies. The CIBMTR uses the Karnofsky / Lansky scale to determine the functional status of the recipient immediately prior to the start of the lympho-depleting or preparative regimen. For the purposes of this manual, the term “immediately prior” represents the pre-infusion work-up phase, or approximately one month prior to the start of the lympho-depleting or preparative regimen.

Select the appropriate performance scale, Karnofsky or Lansky, based on the recipient’s age. Using this scale, select the score (10-100) that best represents the recipient’s activity status immediately prior to the start of the preparative regimen. For an example of the Karnofsky / Lansky scale, see Appendix L.

If a Karnofsky / Lansky score is not documented in the source documentation (e.g., inpatient progress note, physician’s clinic note), data management professionals should not assign a performance score based on analysis of available documents. Rather, a physician or mid-level health care provider (NPs and PAs) should provide documentation of the performance score. Documentation from an RN who has been trained and authorized to determine performance scores may also be used.

The CIBMTR recognizes that some transplant centers prefer to collect and use the ECOG performance score as opposed to the Karnofsky / Lansky score. Although the ECOG and Karnofsky / Lansky performance score systems are based on similar principles, the scales are not the same. For example, the Karnofsky / Lansky scale is described in 11 categories, whereas the ECOG performance status is reported in six categories. Due to the overlap between the two systems, an ECOG score of “one” can represent either “80” or “90” on the Karnofsky / Lansky scale. For centers that collect only an ECOG performance score, CIBMTR will make the following accommodations when auditing the source data:

- Centers collecting ECOG scores should do so using standard practices to ensure accuracy.
For the purposes of CIBMTR reporting, conversion of ECOG to Karnofsky / Lansky should follow a standard and consistent practice. This practice should be clear and reproducible.

For more information regarding converting an ECOG score to a Karnofsky / Lansky score, see Appendix L.

Section Updates:

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
</tr>
</tbody>
</table>

Last modified: Sep 23, 2022
Q113-127: Comorbid Conditions

**Diagnosis of COVID-19 after the start of the lymphodepleting therapy:** Questions 106 – 108 are intended to capture COVID-19 (SARS-CoV-2) infections diagnosed prior to the start of the systemic therapy (e.g., lymphodepleting therapy) / infusion. If a COVID-19 infection is diagnosed after the start of the systemic therapy (e.g., lymphodepleting therapy, report the COVID-19 diagnosis on the post-infusion follow-up form (Cellular Therapy Essential Data Follow-Up (4100) form, Post-HSCT Data (2100) or Post-Transplant Essential Data (2450).

Questions 113-120 will be answered for all recipients.

Questions 121– 127 to be completed for malignant hematologic disorders and solid tumor indications ONLY.

**Question 113:** Has the patient been infected with COVID-19 (SARS-CoV-2) based on a positive test result at any time prior to the start systemic therapy?

SARS-CoV-2 is a novel virus belonging to the coronavirus (CoV) family that emerged in December 2019. The disease caused by this new CoV is known as COVID-19 (coronavirus disease 2019). The new virus is highly contagious and was officially declared a pandemic in March 2020. Transmission is believed to be from person to person through respiratory droplets from coughing and sneezing. Testing for COVID-19 is generally performed on specimens collected from a nasal swab or sputum sample.

Indicate whether or not the recipient has ever had a known COVID-19 (SARS-CoV-2) infection, based on a positive test result, at any time prior to the start of the systemic therapy (e.g., lymphodepleting therapy) or infusion (if no systemic therapy was given).

If the recipient has had a documented COVID-19 (SARS-CoV-2) infection, report **Yes**.

If the recipient has not had a documented COVID-19 (SARS-CoV-2) infection, report **No** and continue with question 116.

If this is a subsequent infusion and the documented COVID-19 (SARS-CoV-2) infection was already reported on previous forms, report No and continue with question 116.

Possible Reporting Scenarios:

An infection **should not** be reported if:

- A recipient has a positive antibody result. The recipient does not have a history of positive COVID-19 results (PCR or antigen).
- The recipient was symptomatic and treated, but COVID-19 diagnostic testing as not performed and / or COVID-19 diagnostic testing was performed and negative.

An infection **should** be reported if:
*A recipient has a positive COVID-19 diagnostic result (PCR or antigen). No treatment was given and/or recipient was symptomatic.

**Question 114: Did the patient require hospitalization for management of COVID-19 (SARS-CoV-2) infection?**

Report **Yes** if the recipient was admitted to the hospital for management of their COVID-19 (SARS-CoV-2) infection. This includes any regular hospital or intensive care unit (ICU) admissions. Otherwise, report **No** and continue with question 116.

**Question 115: Was mechanical ventilation used for COVID-19 (SARS-CoV-2) infection?**

The clinical spectrum of COVID-19 varies from asymptomatic or paucisymptomatic forms to clinical conditions characterized by respiratory failure that necessitates mechanical ventilation and support in an intensive care unit (ICU)). Mechanical ventilation may impact the recipient’s pulmonary function post-infusion. Report **Yes** if the recipient was placed on mechanical ventilation for COVID-19.

**COVID-19 Vaccine**

If the recipient received a COVID-19 vaccine at any time prior to July 2021 (before the COVID-19 vaccine questions were available on the Cellular Therapy Essential Data Pre-Infusion (4000) form), select **Yes** for *Was a vaccine for COVID-19 (SARS-CoV-2) received at any time prior to the start of the systemic therapy* at the first opportunity this form becomes available. When reporting the vaccine date, report the actual date the recipient received the vaccine.

**Question 116: Was a vaccine for COVID-19 (SARS-CoV-2) received at any time prior to the start of systemic therapy?**

Indicate if the recipient received a vaccine for COVID-19 (one dose without a planned second dose, first dose with planned second dose, second dose, third dose and/or booster) at any time prior to the start of the systemic therapy (e.g., lymphodepleting therapy) / infusion.

If the recipient did not receive a vaccine for COVID-19 or it is not known if the recipient received a vaccine, select **No** or **Unknown**, respectively, and continue with question 121.

If this is a subsequent infusion and all vaccine doses have already been reported on previous forms, select **No** and continue with question 121.

If this is a subsequent infusion and some, but not all vaccine doses have already been reported on previous forms, select **Yes** and only report the vaccine doses not previously reported.

**Reporting multiple COVID-19 Vaccine**

FormsNet3SM application: Complete Specify vaccine type and Select dose(s) received questions to report all vaccine doses received by adding an additional instance in the
**Question 117-118: Specify vaccine brand:**

For the vaccine dose being reported, specify the brand of vaccine the recipient received. If the vaccine brand is not listed, select **Other type** and specify.

If the vaccine brand is unknown, leave the data field blank and override the error as 'unknown.'

**Third dose versus Booster dose**

To determine between a third dose and a booster dose, seek clinician clarification, as needed, using the guidelines listed below:

- **Third dose**: An additional primary dose required for recipients who did not build enough protection from their primary vaccine series, typically for immunocompromised individuals.
- **Booster dose**: Administered to recipients who have enough protection after completing their primary vaccine series but then protection decreases over time.

**Primary vaccine series:**
- Two doses of Pfizer-BioNTech or Moderna
- One dose of Johnson & Johnson's Janssen

**Question 120: Select dose received:**

For the vaccine dose being reported, select the vaccine dose(s) the recipient received prior to the start of the systemic therapy/infusion and report the date when the vaccine was received. If the exact date is not known, use the process described in the [General Instructions, Guidelines for Completing Forms](#) and select **Date estimated**.

**Question 121 applies only for malignant hematologic disorder or solid tumor indications.**

**Question 121: Prior viral exposure/infection: (check all that apply)**

Indicate if the recipient was positive for any of the viral exposure or infections listed below. Do not select the viral exposure or infection if the test was performed and the results were negative.

If testing for evidence of prior viral exposure/infection was not performed, select **Not done**.

Select **Not applicable** if testing for evidence of prior viral exposure/infection was performed and all of the results were negative.
**Serologic Tests**
Serologic tests should be completed during the pre-HCT work-up phase, or approximately one month prior to the start of the preparative regimen. If a recipient tests positive for HIV antibody or HIV NAT serologic tests, also complete the HIV Form (Form 2048).

**HTLV1 antibody:** Human T-Lymphotropic virus I/II (HTLV I/II) is a retrovirus in the same class as HIV. HTLV I/II is associated with certain leukemias and lymphomas, as well as demyelinating diseases such as multiple sclerosis.

**Anti-EBV (Epstein-Barr virus antibody):** Epstein-Barr Virus (EBV) is a common virus of the herpes family. It can cause infectious mononucleosis, but in most cases is asymptomatic. EBV establishes a lifelong dormant infection in some cells of the body’s immune system. Serious post-transplant complications related to EBV include EBV viremia (reactivation) and post-transplant lymphoproliferative disease (PTLD).

**Hepatitis B surface antibody:**
Hepatitis B is caused by the hepatitis B virus (HBV). Infection with this virus can cause scarring of the liver, liver failure, liver cancer, and even death. Hepatitis B is spread through infected blood and other body fluids. Acute hepatitis B infection does not usually require treatment because most adults clear the infection. Treatment of chronic infection may be necessary to reduce the risk of cirrhosis and liver cancer.

The hepatitis B surface antibody test reveals the presence of hepatitis B antibodies, indicating previous exposure to HBV (or successful vaccination), but the virus is no longer present, and the person cannot pass on the virus.

**Anti-HBc (hepatitis B core antibody):** The enzyme-linked immunosorbent assay (ELISA) technique tests for the antibody directed against the hepatitis B virus core proteins. The hepatitis B core antibody test can indicate previous HBV infection. Currently there is no licensed confirmatory test for Anti-HBc. If the screening test is reactive, a second Anti-HBc test is performed using a different manufacturer’s test kit.

**HBsAg (hepatitis B surface antigen):** The ELISA or enzyme immunoassay (EIA) techniques test for the presence of proteins produced by the hepatitis B virus. Confirmatory testing is done using a neutralization test. The first marker appears approximately three weeks following infection, and disappears approximately six months later.

**Hepatitis B – NAAT:** The HBV NAAT test is more sensitive than regular serologic tests and is often used in conjunction with those tests to monitor patients with chronic HBV infections. If Hepatitis B – NAAT testing was done, report the results in this section.

**Anti-HCV (hepatitis C antibody):** Hepatitis C is a serious infection caused by the hepatitis C virus (HCV), which attacks the liver and may cause life-long infection. HCV is considered the most serious hepatitis infection because of its significant long-term health consequences. The infection is often asymptomatic, but once established, chronic infection can cause inflammation of the liver. This condition can progress to fibrosis and cirrhosis. In some cases, those with cirrhosis will go on to develop liver failure or liver cancer.
Presence of the antibody in the blood represents exposure to HCV, which is most often spread by blood-to-blood contact. No vaccine against HCV is available.

The ELISA technique tests for antibodies to the HCV. Confirmatory testing is done using the recombinant immunoblot assay (RIBA) test. These tests can determine past exposure to HCV, but not current viral load.

**Hepatitis C – NAAT:** Nucleic acid testing (NAAT) is a combination PCR test that detects the presence of viral genes (HCV RNA) rather than antigens or antibodies. This test allows earlier detection and provides more sensitivity than previously used tests.

**HIV antibody:** HIV infection is caused by exposure to one of two viruses: HIV-1 or HIV-2. HIV-2 is less virulent and has a longer incubation period than HIV-1. Both types of HIV progressively destroy lymphocytes, which are an important part of the body’s immune defense. HIV can lead to acquired immunodeficiency syndrome (AIDS), a condition in which the immune system begins to fail, leading to life-threatening opportunistic infections. Infection with HIV occurs by the transfer of bodily fluids and is present as both free virus particles and virus within infected immune cells.

HIV antibody testing is done using combination ELISA which detects antibodies to the HIV-1 and HIV-2 viruses. HIV-1 is confirmed by Western Blot, which detects specific proteins using gel electrophoresis. There is currently no licensed confirmatory test for HIV-2. If the screening test is reactive, HIV-2 is confirmed by specific ELISA.

The results of HIV assessments are often kept in confidence and may not be reportable to anyone other than the patient and their physician. If HIV testing was done, but the results are not available, do not select this option.

If the result is “positive,” an HIV insert (Form 2048) is also required.

**HIV – NAAT:** Nucleic acid testing (NAAT) is a PCR test that detects the presence of viral genes rather than antigens or antibodies. This test allows earlier detection and provides more sensitivity than previously used tests.

The results of HIV assessments are often kept in confidence and may not be reportable to anyone other than the patient and their physician. If HIV testing was done, but the results are not available, do not select this option.

If the result is “positive,” an HIV insert (Form 2048) is also required.

**Toxoplasmosis antibody:** Toxoplasmosis is caused by the parasitic protozoan Toxoplasma gondii, or T. gondii. Toxoplasmosis is spread through ingestion of contaminated food or water or contact with infected cat feces. T. gondii infection is usually subclinical in healthy individuals, but infection can cause serious symptoms in pregnant women and immunocompromised individuals. Chronic, dormant T. gondii infection may follow initial exposure, and can then reoccur. Severe toxoplasmosis can affect the brain, eyes, and other organs and can cause permanent organ damage.
Testing for antibodies to T. gondii is generally done by enzyme-linked immunosorbent assay (ELISA) or chemiluminescent immunoassay (CIA). These immunoassays can be used to detect IgM and/or IgG antibodies to T. gondii. The presence of IgM antibodies indicates a recent or current infection, usually within the past four to six months. The presence of IgG antibodies indicates a previous infection and confers a long-term immune response to the virus. Results may be expressed as quantified antibody titer; in this case, the laboratory or test kit manufacturer will provide reference ranges to determine if the result is considered positive, indeterminate, or negative. Confirmatory testing is available to verify a positive serological result; this is done by Toxoplasma Serological Profile (TSP), which is a panel of multiple antibody ELISAs and agglutination testing.

Comorbidities

Prior to answering Were there any co-existing diseases or organ impairment present according to the HCT comorbidity index (HCT-CI) question, review the list of co-existing disease(s) and/or organ impairments listed below.

Question 122: Were there any co-existing diseases or organ impairment present according to the HCT comorbidity index (HCT-CI)?

Please report co-morbidities that were detected within six months of the cellular therapy, which is different than HCT reporting. The 6 month rule applies to assessments that need to be performed in order to determine if a comorbidity is present (i.e., PFT for pulmonary, liver values for hepatic, creatinine for renal, BMI for obesity, etc.). If the co-morbidity is denoted as “ANY history”, the 6 month rule does not apply.

Hepatic and Renal Comorbidities

In addition to the guidelines listed on the Pre-TED form, include the following time-specific guidelines when reporting hepatic and renal comorbidities

Hepatic Comorbidity: The assessment of liver function tests (ALT, AST and/or Total Bilirubin) has to include at least 2 values per test on two different days within a period extending between day -24 and the start of the systemic therapy regimen/lymphodepleting therapy. If no therapy was given, then it would be day -24 and the cellular therapy infusion date. If only a single value was reported in this time period, use the most recent test performed between days -40 & -25 as the second value. When determining the severity of the hepatic comorbidity, the value closest to the start of the systemic therapy regimen/lymphodepleting therapy should be used. If the liver function test values closest to the start of the preparative regimen do not meet the criteria specified above, a hepatic comorbidity should not be reported.

Renal (Moderate/Severe) Comorbidity: Serum creatinine > 2 mg/dL or > 177 μmol/L, as detected in at least two lab values on two different days within a period extending between day -24 and the start of the systemic therapy regimen/lymphodepleting therapy. If no systemic therapy was given, then it would be day -24 and the cellular therapy infusion date. If only a single value was reported in this time period, use the most recent test performed between days -40 & -25 as the second value. If the serum creatinine value closest to the start of the systemic therapy regimen/lymphodepleting therapy did not meet the criteria

Report **Yes** if the recipient has a documented history and / or current diagnosis of any of the following:

**Documented Medical History**

- Arrhythmia that has required specific antiarrhythmic treatment
- Cardiac
- Cerebrovascular disease
- Inflammatory bowel disease
- Peptic ulcer
- Rheumatologic
- Prior malignancy, requiring treatment

**Current Diagnosis at the Time of Pre-Infusion Evaluation**

- Diabetes
- Heart valve disease
- Hepatic, mild
- Hepatic, moderate/severe
- Infection
- Obesity
- Psychiatric disturbance
- Pulmonary, moderate
- Pulmonary, severe
- Renal, moderate/severe

2 Ejection fraction (EF) $\leq 50\%$ should be reported only if present on most recent test

3 Excluding asymptomatic mitral valve prolapse

4 Including any history of hepatitis B or hepatitis C infection

5 If the PFT lists both a "control" FEV1 and a "post-dilator" FEV1, the "control" FEV1 should be used to determine if a pulmonary comorbidity is present.

6 Including renal transplantation at any time in the patient's history

*Report all comorbidities including those that are considered complications of the primary disease for infusion. See examples below.*
Examples of complications of the primary disease for infusion that should be reported as comorbidities.

- A patient with sickle cell had a stroke prior to infusion, the comorbidity to report would be “cerebrovascular disease”.
- A toddler with Hurler Syndrome has cardiomyopathy, cardiac valvular disease and an ejection fraction of 45%, the comorbidities to report would be “cardiac” & “heart valve disease”.

The intent of this question is to identify serious pre-existing conditions that may have an effect on the outcome of the cellular therapy. For the purposes of this manual, the term “clinically significant” refers to conditions that are being treated at the time of pre-infusion evaluation or are in the recipient’s medical history and could cause complications post-infusion. Conditions listed in the recipient’s medical history that have been resolved (e.g., appendectomy), and/or that would not pose a concern during or after the infusion should not be reported.

Additionally, for the purposes of this manual, the term “at the time of patient assessment” is defined as the pre-infusion evaluation period performed within 6 months prior to the start of the lympho-depleting or systemic therapy. If the recipient does not have a documented history of clinically significant disease(s) or organ impairment(s), check “no” and submit the form.

For information regarding reporting clinically significant co-existing disease or organ impairment, see Appendix J.

**Question 123: Co-existing diseases or organ impairments**

Indicate if the recipient had any of the co-existing diseases or organ impairments listed below. The definitions for each of the categories below are taken from Sorror, M. L. (2013). How I assess comorbidities before hematopoietic cell transplantation. Blood, 121(15), 2854-2863.

- **Arrhythmia**: Any history of any type of arrhythmia that has necessitated the delivery of a specific antiarrhythmic agent. Examples include, but are not limited to, atrial fibrillation or flutter, sick sinus syndrome, and ventricular arrhythmias requiring treatment.

- **Cardiac**: Any history of coronary artery disease (one or more vessel coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure, myocardial infarction, and/or ejection fraction ≤ 50% (shortening fraction < 26% for pediatric recipients) on the most recent test.

- **Cerebrovascular disease**: Any history of transient ischemic attack, subarachnoid hemorrhage, and/or cerebral thrombosis embolism, or hemorrhage.

- **Diabetes**: Diabetes or steroid-induced hyperglycemia requiring continuous treatment with insulin or oral hypoglycemics in the last 4 weeks.

- **Heart valve disease**: Moderate or severe valve stenosis or insufficiency (mitral, aortic, tricuspid, or pulmonary) as determined by the most recent heart evaluation by an echocardiogram, prosthetic mitral or aortic valve, and/or symptomatic mitral valve prolapse. This does not include a documented medical
history of heart valve disease.

**Hepatic (mild):** Chronic hepatitis, bilirubin > upper limit of normal to 1.5x upper limit of normal, or AST/ALT > upper limit of normal to 2.5x upper limit of normal, or any history of hepatitis B or hepatitis C infection. See note in question 122.

**Hepatic (moderate/severe):** Liver cirrhosis, bilirubin > 1.5x upper limit of normal, or AST/ALT > 2.5x upper limit of normal. See note in question 122.

**Infection:** Documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0.

**Inflammatory bowel disease:** Any history of Crohn’s disease or ulcerative colitis requiring treatment.

**Obesity:** Patients with a body mass index > 35 kg/m2 or BMI-for-age ≥ 95% (pediatric recipients only) during pre-transplant work-up period.

**Peptic ulcer:** Any history of peptic ulcer confirmed by endoscopy and requiring treatment.

**Psychiatric disturbance:** The presence of any mood, anxiety, or other psychiatric disorder requiring continuous treatment during the last four weeks. Examples include, but are not limited to, depression, anxiety, Attention-Deficit Disorder (ADD), Attention-Deficit Hyperactivity Disorder (ADHD), bipolar disorder, and schizophrenia requiring psychiatric consult or treatment in the last 4 weeks. Do not report a psychiatric comorbidity if therapy was given “as needed” for any mood, anxiety, or other psychiatric disorder.

**Pulmonary (moderate):** Corrected diffusion capacity of carbon monoxide (e.g., DLCOc, DLCOcorr, DLCO) and/or FEV1 66-80% or dyspnea on slight activity at transplant. Use the Dinakara equation below to determine the DLCOc if only an uncorrected value is provided. For recipients assessed by a post-bronchodilator test, only the pre-bronchodilator FEV1 values are considered for evaluation of pulmonary comorbidity.

Dinakara Equation: \[ DLCOc = \frac{\text{uncorrected DLCO}}{0.06965 \times \text{hemoglobin g/dL}} \]

**Pulmonary (severe):** Corrected diffusion capacity of carbon monoxide (e.g., DLCOc, DLCOcorr, DLCO) and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant. Use the Dinakara equation above to determine the DLCOc if only an uncorrected value is provided. For recipients assessed by a post-bronchodilator test, only the pre-bronchodilator FEV1 values are considered for evaluation of pulmonary comorbidity.

**Renal (moderate / severe):** Serum creatinine > 2 mg/dL or > 176.8 μmol/L, or on any form of dialysis at transplant, or prior renal transplantation. See note in question 122.

If renal (moderate / severe) comorbidity is selected, complete question 124.
**Rheumatologic:** Any history of systemic lupus erythematosus, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

**Prior malignancy, specify:** Any solid tumor(s) and / or hematologic malignancy(ies) that have been treated at any time point in the patient’s past history. A history of any benign tumor(s) should not be reported.

If the recipient is receiving a cellular therapy for a disease that has transformed from one disease to another, the original malignancy should not be reported in this section. Details regarding disease transformation will be captured on the Pre- TED Disease Classification Form (Form 2402). For more information regarding disease combinations and transformations, refer to the Common Disease Combinations and Common Disease Transformations tables in the Primary Disease for HCT / Cellular Therapy section of the Disease Classification Form (Form 2402).

If prior malignancy is selected, complete question 125.

The physician performing the recipient's pre-infusion evaluation may use the HCT Co- Morbidity Index (HCT-CI) to document co-morbid conditions (see Appendix J).

**Question 124: Was the recipient on dialysis immediately prior to start of lymphodepleting therapy?**

Indicate if the recipient was dialysis, hemodialysis, or peritoneal dialysis dependent within approximately one month prior to the start of the lymphodepleting therapy.

**Question 125-127: Specify prior malignancy (check all that apply)**

Specify the recipient’s prior solid tumor(s) and / or hematologic malignancy(ies). If Other hematologic malignancy is selected, specify the prior hematologic malignancy in question 126. If Other solid tumor is selected, specify the prior solid tumor in question 127.


**Section Updates:**

<table>
<thead>
<tr>
<th>Question Number</th>
<th>Date of Change</th>
<th>Add/ Remove/ Modify</th>
<th>Description</th>
<th>Reasoning (If applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>121</td>
<td>2/8/23</td>
<td>Modify</td>
<td>Updated the text in the blue box below question 121: Serologic tests should be completed during the pre-HCT work-up phase, or approximately one month prior to the start of the preparative regimen. If a recipient tests positive for Hepatitis B core antibody (Anti HBc), Hepatitis B surface antigen (HBsAg),</td>
<td>F2047 is not used for cell therapy reporting.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis B NAAT, Hepatitis C antibody (Anti HCV), and/or Hepatitis C NAAT serologic tests, also complete the HEP Form (Form 2047). If a recipient tests positive for HIV antibody or HIV NAT serologic tests, also complete the HIV Form (Form 2048).</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>122</strong></td>
<td><strong>9/29/2022</strong></td>
<td>Add</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Added blue note box above question 122: Prior to answering Were there any co-existing diseases or organ impairment present according to the HCT comorbidity index (HCT-CI) question, review the list of co-existing disease(s) and/or organ impairments listed below.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>122</strong></td>
<td><strong>9/29/2022</strong></td>
<td>Modify</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Updated text in red: Current Diagnosis at the Time of Pre-Infusion Evaluation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>122</strong></td>
<td><strong>9/29/2022</strong></td>
<td>Modify</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moved ‘Rheumatologic’ and ‘Prior malignancy, requiring treatment’ to the Documented medical history list. Added ‘heart value disease’ under Current Diagnosis at the Time of Pre-Infusion Evaluation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>122</strong></td>
<td><strong>9/29/2022</strong></td>
<td>Modify</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Removed text from the blue note box: Hepatic and Renal Comorbidities Report all comorbidities including those that are considered complications of the primary disease for infusion. See examples below.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Added text box to match Pre-TED 2400 form manual*

*Original text was ‘HCT’, which does not apply in the cell therapy manuals*

*First two options were mislabeled, third option was missing*

*This blue note applies to all comorbidities, not just hepatic and renal comorbidities*

*Last modified: Feb 08, 2023*